Alyea Therapeutics Corporation Inc., a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), is set to engage in key events during the 43rd Annual J.P. Morgan Healthcare Conference Week, taking place from January 13-16, 2025, in San Francisco, California. The company is at the forefront of developing innovative solutions aimed at ending the opioid crisis, with its lead asset, JAN123, a novel formulation of Low Dose Naltrexone (LDN), preparing for its pivotal Phase III study. This approach is seen as a potential landmark in treating pain through non-addictive and non-sedating means, with additional applications for managing chronic pain.
Dr. Amol Soin, Chief Executive Officer of Alyea, will participate in three days of meetings, presentations, and discussions from January 13-15, 2025. He is scheduled to present at the Biotech Showcase on January 13, 2025, at the Hilton San Francisco and as a RESI JPM IPC Finalist on January 14 at the San Francisco Marriott Marquis Hotel. Additionally, Dr. Soin and ALT5 Sigma CEO, Peter Tassiopoulos, will attend the prestigious Nasdaq Opening Bell Ceremony on January 13, 2025, marking the beginning of the 43rd Annual J.P. Morgan Healthcare Conference.
During the Conference Week, Dr. Soin and Mr. Tassiopoulos will engage in one-on-one investor and partnering meetings to provide updates on the anticipated regulatory pathway for the pivotal trial of its LDN for Chronic Regional Pain Syndrome (CRPS) candidate and discuss its Clear Patch medication delivery platform, currently in pre-clinical development.
ALT 5 Sigma plans to complete the spin-off of its healthcare assets into Alyea in the first half of 2025, allowing each entity to focus on its unique business needs. Alyea is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain, offering a strategic option for physicians averse to exposing patients to addictive opioids.
